On Wednesday, Lake Street Capital Markets maintained its Buy rating and $75.00 price target for Tandem Diabetes Care (NASDAQ:TNDM). The firm's stance comes after Tandem's stock experienced a notable decline on Tuesday. The sell-off was attributed to market reactions to announcements from Eli Lilly (NYSE:LLY) and Medtronic (NYSE:MDT), which are seen as potential future competitors in the diabetes care market.
Eli Lilly recently shared positive findings on Trizepatide's effects on individuals at risk for Type 2 diabetes. Similarly, Medtronic reported impressive results and discussed a new partnership with Abbott, aiming to combine Abbott's FreeStyle Libre technology with Medtronic's insulin delivery devices. These developments have caused some concern among Tandem investors regarding future competition.
Despite these concerns, Lake Street Capital Markets believes that the recent news will not affect Tandem's business in the short term. The analyst from the firm suggested that it could take years for Eli Lilly and Medtronic to commercialize products that might compete with Tandem's offerings. The firm emphasized that investor fears are often an overreaction and reassured that the current developments should not impact Tandem's growth in the next two years at the earliest.
The analyst encouraged investors to look at the facts and assess the probabilities regarding Tandem's future performance. With a continued positive outlook on Tandem Diabetes Care, Lake Street Capital Markets reaffirmed its Buy rating and $75 price target, suggesting confidence in the company's market position and long-term prospects.
In other recent news, Tandem Diabetes Care reported significant second-quarter sales growth of $222 million in 2024, marking a milestone with the successful launch of the Tandem Mobi pump platform. The sales growth, remarkable both in the U.S. and international markets, puts the company on track to achieve its 15% sales growth target for the year, with year-to-date sales at $415 million.
In addition, Canaccord Genuity initiated coverage of Tandem with a Buy rating, based on the potential for Tandem to expand its market share through its existing product lineup and future innovations. The firm's analysis indicates that Tandem is poised to capitalize on advancements in automated insulin delivery (AID) technology, with the anticipated FDA clearance for AID use in insulin-intensive Type 2 diabetes by mid-2025 seen as a catalyst for significant long-term growth.
Furthermore, Tandem is integrating Abbott's FreeStyle Libre 3+ sensor and investing in digital health platforms, with a goal to reach a million users in the next five years. The company projects 2024 sales to be between $885 million and $892 million, with a 51% gross margin and breakeven adjusted EBITDA.
InvestingPro Insights
As Tandem Diabetes Care (NASDAQ:TNDM) navigates through competitive pressures, recent data from InvestingPro provides a mixed picture of the company's financial health and market performance. Despite concerns over potential competition, Tandem's aggressive share buybacks, as noted in an InvestingPro Tip, signal a strong belief from management in the company's value. However, it's worth noting that analysts have tempered their expectations, with 12 analysts revising their earnings downwards for the upcoming period, and a consensus that the company may not achieve profitability this year.
InvestingPro Data shows a market capitalization of $2.78 billion, with a high Price / Book multiple of 11.87 as of the last twelve months leading up to Q2 2024. This valuation metric may raise questions about the stock's current pricing relative to its tangible assets. Furthermore, the company's revenue growth stands at a modest 0.72% for the same period, reflecting a challenging growth environment.
On the brighter side, Tandem has demonstrated a high return over the last year, with a 50.88% price total return, and a significant 85.94% price uptick over the last six months. These figures suggest a robust market performance despite the headwinds faced by the company. For investors looking for deeper analysis and more InvestingPro Tips, additional insights are available, including metrics on debt levels, liquidity, and more detailed earnings projections at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.